Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada

MT Newswires Live
Apr 30

Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.

The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.

Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10